K. Daniels

Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study.

Jacqueline Whetteckey, H. Woerle, J. Thrasher, 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin

Jacqueline Whetteckey, J. Thrasher, K. Daniels, 2012, Expert opinion on pharmacotherapy.

Risk factors for hospitalization in a cohort with type 1 diabetes. Wisconsin Diabetes Registry.

M. Palta, C. Allen, G. Shen, 1997, American journal of epidemiology.

A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale

Tyrone D. Cannon, D. Mathalon, S. Woods, 2020, Early intervention in psychiatry.

Risk factors for frequent and severe hypoglycemia in type 1 diabetes.

M. Palta, C. Allen, D. D'alessio, 2001, Diabetes care.

A Phase IC Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Cognitive Outcomes of BI 409306 in Patients with Mild-to-Moderate Schizophrenia

M. Sand, Solen Pichereau, K. Daniels, 2017, Neurology and Therapy.

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

R. Keefe, G. Gründer, J. Cordes, 2017, Schizophrenia bulletin.